Concern on Impact to Commercial Market: “Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our medicines and drug candidates”
All entries for: Neurological Diseases
November 9, 2022
Beigene
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
November 8, 2022
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Concerns on Impact to Commercial Market & Development Decisions: “These risks as to pricing may further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if the pricing of any of our products are the subject of Medicare price negotiations. As a result, these risks may also impact the development decisions we make with respect to our products.”
Disease Area: Neurological Diseases
Drug Type: Biologic
November 8, 2022
Cerevel Therapeutics
Negative Outlook
Cambridge, MA
201-500 employees
201-500 employees
Impact TBD: “The effect of IRA on our business and the healthcare industry in general is not yet known. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company’s revenue generated from the sale of any approved products. Even if we do receive a favorable coverage determination for our products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time”
Disease Area: Neurological Diseases
Drug Type: Small Molecule
October 28, 2022
Sanofi
Neutral Outlook
Paris, France
50,001+ employees
50001+ employees
SA CO Paul Hudson stated that the IRA “…will likely create significant uncertainties across our industry,” highlighting investments into future R&D. However, Mr. Hudson noted that SA is “well positioned in the short term” to navigate IRA challenges. 1. And that the orphan drug exemption to price setting is only applicable to drugs with only one indication, which disincentivizes pursuing additional indications 2. The discrepancy between the eligibility dates of biologics and small-molecule drugs for price setting
Disease Area: Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
October 25, 2022
Biogen
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
IRA is Notable Example of Pricing Pressure: “Drug prices are under significant scrutiny in the markets in which our products are prescribed, for example the Inflation Reduction Act of 2022 (the IRA) has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis” • Uncertainty: “The overall impact that the IRA will have on our business, results of operations and financial condition, and the impact on the pharmaceutical industry as a whole is not yet known. We will continue to assess as further information becomes available”
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
